Web[SHANGHAI, DONGGUAN and SAN DIEGO] Fosun Kite Biotechnology (“Fosun Kite”), Phanes Therapeutics, and Phanes Biopharmaceuticals, Ltd. (“Phanes”) recently formed an important strategic alliance. ... Ltd and U.S. Kite Pharma (a Gilead company), Fosun Kite is dedicated to the advancement of innovative immuno-cell therapy and its ... WebVP & CTO, Fosun Pharma. Founding CEO of Fosun Kite Biotech, completed tech transfer, registration trial and market authorization application for Yescarta in China (the first CAR-T product) in less than three years. COO of CBMG (Cellular Biomedical Group), managed production and clinical trials of stem cell and CAR-T therapies.
China Approves Its First CAR-T Cell Therapy - Caixin Global
WebJun 24, 2024 · As a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd and Kite Pharma, Inc., Fosun Kite is dedicated to the advancement and commercialization of innovative cell therapies in ... WebMar 28, 2024 · Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* ("Fosun Pharma"; stock code: 600196. SH, 02196. SH, 02196. HK) is a global … dow jones average close today
China
WebJun 23, 2024 · Fosun Pharma Kite Biotechnology will market Yescarta in China, a treatment meant for adults diagnosed with B-cell lymphoma that have not responded to 2 other treatments or have relapsed. Terence O’Sullivan, VP, International Region at Kite, stated, “In relapse or refractory LBCL, current standard-of-care is associated with poor … WebJan 10, 2024 · Each party will share in any profits from the joint venture with Kite Pharma receiving 40 percent and Fosun Pharma receiving 60 percent. Kite will also receive an … WebJan 15, 2024 · In 2024, Kite Pharma Inc. (a Gilead company) formed a PRC onshore joint venture with Fosun Pharmaceuticals in Shanghai FTZ, named Fosun Kite Biotechnology Co. which is owned 50% by Kite Pharma and 50% by Fosun (“Fosun Kite”). These three firms have become BIG NAMES in the cell therapy industry in China. cklq news